Insights from the dabigatran versus warfarin in patients with atrial fibrillation (RE-LY) trial

被引：8

作者：

Khoo, Chee W. ^{[1
]}

Lip, Gregory Y. H. ^{[1
]}

机构：

[1] Univ Birmingham, City Hosp, Ctr Cardiovasc Sci, Birmingham B18 7QH, W Midlands, England

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 04期

关键词：

atrial fibrillation; dabigatran; direct thrombin inhibitor; stroke; DESIGN;

D O I：

10.1517/14656560903530691

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Oral anticoagulants such as warfarin have been used widely for the treatment of venous thromboembolism and stroke prevention in atrial fibrillation (AF) patients. Warfarin has significant limitations and also requires frequent monitoring. Thus, there is an unmet need, with the quest for alternative oral anticoagulants with stable pharmacokinetics and pharmacodynamics that do not need monitoring. The paper under evaluation provides us with up-to-date information on the safety and efficacy of a new oral anticoagulant, dabigatran, compared with warfarin for stroke prevention in AF patients.</.

引用

页码：685 / 687

页数：3

共 50 条

[21] Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation - a RE-LY Trial Analysis
Hijazi, Ziad
Hohnloser, Stefan H.
Oldgren, Jonas
Andersson, Ulrika
Connolly, Stuart J.
Eikelboom, John W.
Ezekowitz, Michael D.
Reilly, Paul A.
Siegbahn, Agneta
Yusuf, Salim
Wallentin, Lars
CIRCULATION, 2013, 128 (22)
[22] Comparison of bleeding risk scores in patients with atrial fibrillation: insights from the RE-LY trial
Proietti, M.
Hijazi, Z.
Andersson, U.
Connolly, S. J.
Eikelboom, J. W.
Ezekowitz, M. D.
Lane, D. A.
Oldgren, J.
Roldan, V.
Yusuf, S.
Wallentin, L.
JOURNAL OF INTERNAL MEDICINE, 2018, 283 (03) : 282 - 292
[23] Dabigatran for the prevention of stroke in atrial fibrillation: is RE-LY reliable?
Marin, Francisco
Roldan, Vanessa
Lip, Gregory Y. H.
EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (08) : 1087 - 1090
[24] Switching patients from warfarin to dabigatran therapy: To RE-LY or not to rely
Sawaya, Fadi J.
Musallam, Khaled M.
Arnaout, Samir
Rabah, Ali
Sawaya, Jaber
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 154 (02) : E27 - E28
[25] DABIGATRAN VERSUS WARFARIN IN ATRIAL FIBRILLATION PATIENTS WITH LOW, MODERATE AND HIGH CHADS2 SCORE: A RE-LY SUBGROUP ANALYSIS
Oldgren, Jonas
Alings, Marco
Darius, Harald
Eikelboom, John
Ezekowitz, Michael
Parekh, Amit
Pogue, Janice
Reilly, Paul
Yusuf, Salim
Wallentin, Lars
Connolly, Stuart
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
[26] DABIGATRAN VERSUS WARFARIN AND IMPACT OF CHAD2-VASC SCORE ON OUTCOME IN ATRIAL FIBRILLATION PATIENTS: A RE-LY SUBGROUP ANALYSIS
Oldgren, Jonas
Ezekowitz, Michael D.
Alings, Marco
Diener, Hans-Christoph
Reilly, Paul A.
Yusuf, Salim
Wallentin, Lars
Connolly, Stuart
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (14) : E7 - E7
[27] Dabigatran versus warfarin in patients with pacemaker or defibrillator wires in the RE-LY trial: the role of contact activation
Ezekowitz, M. D.
Parise, H.
Noack, H.
Brueckmann, M.
Clemens, A.
Connolly, S.
Reilly, P.
Yusuf, S.
Wallentin, L.
EUROPEAN HEART JOURNAL, 2014, 35 : 1115 - 1115
[28] Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial
Hori, Masatsugu
Connolly, Stuart J.
Ezekowitz, Michael D.
Reilly, Paul A.
Yusuf, Salim
Wallentin, Lars
CIRCULATION JOURNAL, 2011, 75 (04) : 800 - 805
[29] RE-LY trial: both warfarin and dabigatran etexilate reduce GFR
Reactions Weekly, 2015, 1558 (1) : 11 - 11
[30] Letter by Freeman et al Regarding Article, "Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial"
Freeman, W. David
Kuo, Ruth
Aguilar, Maria I.
STROKE, 2012, 43 (07) : E63 - E63

← 1 2 3 4 5 →